Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
On Monday, April 28, 2025, built -in Wegovy injections, organized in Waterbury, Vermont, USA.
SHELBIA CHOROS | Bloomberg | Gets the image
Shares Novo nordisk On Monday, he rose on Monday after the Wegovy’s obesity drug received accelerated approval from nutrition and US medicines for the treatment of serious liver disease.
On Friday, the company said it was granted permission to treat metabolic dysfunction associated with steotohepatitis (MASH) in adults with moderate and advanced liver fibrosis combined with a reduced calorie diet.
Stock rose further in the afternoon after the company said it would reduce the cost of Ozempic For patients who pay cash up to $ 499 a month, less than half a monthly price in the US.
Novo Nordisk shares increased by 7.4% to 14:25 in London (9:25 am).
The statement makes Wegovy the first GLP-1 class treatment, which can be allowed for MASH, a progressive liver condition affecting 5% adults in the US, the US liver reports.
It also promotes the use of drugs outside the treatment of diabetes and obesity and develops its presence in the metabolic market. Approval follows from a number of studies that show Drug efficiency When the risk of heart attack, stroke and death is reduced from cardiovascular causes.
“Vezhavi is now clearly positioned as the first and only GLP-1 treatment, approved for MASH, supplementing the already proven weight loss, cardiovascular benefits and wide volume of evidence related to Semaglutide,” said Martin Holst Lange, executive vice president of Novo Novo.
Accelerated approval was based on the first stage of the trial in which Novo Nordisk said Demonstrated “statistically significant and excellent improvement” in liver fibrosis compared to placebo.
During the study, the company stated that almost two -thirds (62.9%) people who received vegova reached the permission of Steathepatitis without worsening liver fibrosis, compared to 34.3%who injected placebo.
More than a third (36.8%) of those who treated Wegovy have reached improvement of liver fibrosis without detergents in 72 weeks, compared to 22.4%that received placebo. The second stage of the study is expected in 2029.
Novo Nordisk said on Friday that Vegavi would be immediately available in the US for MASH. Currently, the only other treatment. approved With FDA, Madrigal Pharmaceuticals’ Rezdiffra, which was cleared in 2024.
